• Sensex79454.47-880.34(-1.1%)
  • Nifty24008-265.8(-1.1%)
  • USDINR84.570.03(0.03%)
Online tarding Partner With Us
BSE Prices delayed by 5 minutes ! Prices as on   May 09, 2025 - 3:59PM   ABB India 5443.45 [ 3.22% ]ACC 1813.2 [ 0.25% ]Ambuja Cements 527.9 [ 0.62% ]Asian Paints Ltd. 2303 [ 0.02% ]Axis Bank Ltd. 1154.3 [ -1.44% ]Bajaj Auto 7683.5 [ -0.58% ]Bank of Baroda 220.15 [ 1.36% ]Bharti Airtel 1850 [ -1.21% ]Bharat Heavy Ele 216.75 [ -0.28% ]Bharat Petroleum 306.7 [ -0.34% ]Britannia Ind. 5425 [ 0.59% ]Cipla 1476.8 [ -0.67% ]Coal India 382.65 [ -0.66% ]Colgate Palm. 2551.15 [ 0.16% ]Dabur India 462.85 [ -1.36% ]DLF Ltd. 637 [ -2.79% ]Dr. Reddy's Labs 1156.4 [ 0.67% ]GAIL (India) 181.7 [ -1.22% ]Grasim Inds. 2635 [ -2.42% ]HCL Technologies 1569.15 [ -0.63% ]HDFC Bank 1889.2 [ -1.93% ]Hero MotoCorp 3854.3 [ 1.36% ]Hindustan Unilever L 2333.95 [ -0.90% ]Hindalco Indus. 625.8 [ 1.20% ]ICICI Bank 1388.7 [ -3.16% ]Indian Hotels Co 719.4 [ -4.10% ]IndusInd Bank 817.5 [ -0.95% ]Infosys L 1507.45 [ -0.25% ]ITC Ltd. 423.9 [ -1.50% ]Jindal St & Pwr 857.2 [ 1.39% ]Kotak Mahindra Bank 2110 [ -0.11% ]L&T 3445.7 [ 3.77% ]Lupin Ltd. 2029.35 [ 0.77% ]Mahi. & Mahi 2982.75 [ -1.59% ]Maruti Suzuki India 12267 [ -1.00% ]MTNL 39.04 [ -2.18% ]Nestle India 2323.8 [ -0.74% ]NIIT Ltd. 129.5 [ 0.90% ]NMDC Ltd. 64.36 [ 0.96% ]NTPC 334.6 [ -1.52% ]ONGC 234.25 [ 0.49% ]Punj. NationlBak 91.95 [ 0.66% ]Power Grid Corpo 299.55 [ -2.70% ]Reliance Inds. 1377.75 [ -1.93% ]SBI 779.4 [ 1.39% ]Vedanta 407.85 [ 0.20% ]Shipping Corpn. 162 [ -0.55% ]Sun Pharma. 1744.5 [ -1.23% ]Tata Chemicals 820 [ 1.55% ]Tata Consumer Produc 1113 [ -0.19% ]Tata Motors 708.5 [ 3.90% ]Tata Steel 142.75 [ -0.63% ]Tata Power Co. 371.15 [ 0.32% ]Tata Consultancy 3442.2 [ -0.15% ]Tech Mahindra 1492.35 [ -0.64% ]UltraTech Cement 11379.05 [ -2.15% ]United Spirits 1528.4 [ -0.59% ]Wipro 241.9 [ 0.27% ]Zee Entertainment En 115.85 [ 4.28% ]
BSE

MARKETS

News Details

( As on 24/04/2025 11:20)

Lupin receives U.S. FDA approval for Tolvaptan Tablets

Lupin Limited, a leading global pharmaceutical company, has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Tolvaptan Tablets in strengths of 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg.

These tablets are the generic equivalent of Jynarque® Tablets by Otsuka Pharmaceutical Company, Ltd. Lupin is the exclusive first-to-file applicant for this product, securing 180 days of marketing exclusivity in the U.S. The product will be manufactured at Lupin’s Nagpur facility in India and is expected to be launched soon.

Tolvaptan is prescribed to slow the progression of kidney function decline in adults at risk of rapidly advancing autosomal dominant polycystic kidney disease (ADPKD).

“We are thrilled to receive FDA approval for our generic version of Tolvaptan,” said Vinita Gupta, CEO of Lupin. “This approval represents a strategic move into the nephrology segment and reflects our dedication to addressing critical unmet medical needs worldwide.”

Tolvaptan Tablets (reference listed drug Jynarque®) recorded estimated annual U.S. sales of approximately USD 1.47 billion for the fiscal year ending December 31, 2024.